Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting the TLK1-MK5 Axis Suppresses Prostate Cancer Metastasis.

Cancers·2025
Same author

Beyond the Horizon: Rethinking Prostate Cancer Treatment Through Innovation and Alternative Strategies.

Cancers·2025
Same author

TLK1>Nek1 Axis Promotes Nuclear Retention and Activation of YAP with Implications for Castration-Resistant Prostate Cancer.

Cancers·2024
Same author

Exploiting TLK1 and Cisplatin Synergy for Synthetic Lethality in Androgen-Insensitive Prostate Cancer.

Biomedicines·2023
Same author

Untousling the Role of Tousled-like Kinase 1 in DNA Damage Repair.

International journal of molecular sciences·2023
Same author

TLK1-mediated RAD54 phosphorylation spatio-temporally regulates Homologous Recombination Repair.

Nucleic acids research·2023

Related Experiment Video

Updated: Jul 23, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K

Targeting Prostate Cancer, the 'Tousled Way'.

Siddhant Bhoir1, Arrigo De Benedetti1

  • 1Department of Biochemistry and Molecular Biology, LSU Health Shreveport, Shreveport, LA 71103, USA.

International Journal of Molecular Sciences
|July 14, 2023
PubMed
Summary

Human tousled-like kinase 1 (TLK1) drives prostate cancer (PCa) adaptation to androgen deprivation therapy (ADT). Targeting TLK1 may prevent progression to incurable metastatic castration-resistant PCa (mCRPC).

Keywords:
ADTARPCaTLK1 signalingand pathway inhibition

More Related Videos

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.6K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K

Related Experiment Videos

Last Updated: Jul 23, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.6K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Prostate Cancer Research

Background:

  • Androgen deprivation therapy (ADT) is a primary treatment for prostate cancer (PCa).
  • Resistance to ADT leads to castration-resistant PCa (CRPC), often with poor prognosis.
  • Mechanisms of ADT resistance include androgen receptor (AR)-dependent and -independent pathways.

Purpose of the Study:

  • To identify key mediators of PCa adaptation to ADT.
  • To elucidate the role of human tousled-like kinase 1 (TLK1) in PCa progression.
  • To explore TLK1 as a therapeutic target for advanced PCa.

Main Methods:

  • Identification of TLK1 as a mediator of PCa cell adaptation to ADT.
  • Analysis of TLK1's role in promoting androgen-independent growth, apoptosis inhibition, and metastasis.
  • Review of existing literature on TLK1 biology in PCa.

Main Results:

  • TLK1 is identified as a crucial early mediator in PCa cell adaptation to ADT.
  • TLK1 promotes androgen-independent growth and facilitates cell motility and metastasis.
  • TLK1 plays a significant role in the transition from androgen-sensitive to androgen-insensitive PCa.

Conclusions:

  • TLK1 is a key driver of resistance to androgen deprivation therapy in prostate cancer.
  • Targeting TLK1 signaling may offer a novel strategy to prevent progression to metastatic castration-resistant PCa (mCRPC).
  • Further research into TLK1 inhibitors could provide new therapeutic avenues for treating advanced PCa.